(73 days)
Not Found
No
The description focuses on the mechanical function of the device and synchronization with the cardiac cycle, with no mention of AI or ML technologies.
Yes
The device is a "cardiac assist device" that "supports the heart's left ventricle by increasing coronary perfusion and reducing left ventricular work" for various cardiac conditions, which aligns with the definition of a therapeutic device.
No
The device description clearly states that the Intra-Aortic Balloon Pumps "support the heart's left ventricle" and "increase coronary perfusion and reducing left ventricular work" through mechanical actions (inflation and deflation of a balloon). This indicates a therapeutic or supportive function, not a diagnostic one.
No
The device description clearly states it is an Intra-Aortic Balloon Pump (IABP), which is a physical cardiac assist device involving a balloon and its inflation/deflation mechanism. This is hardware, not software only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use/Indications for Use: The intended use describes a device that is used in vivo (within the body) to assist the heart's function by inflating and deflating a balloon in the aorta. This is a therapeutic intervention, not a diagnostic test performed on samples taken from the body.
- Device Description: The description clearly outlines a cardiac assist device that physically interacts with the patient's circulatory system.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.) or providing diagnostic information based on such analysis.
IVD devices are designed to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This device does not fit that description.
N/A
Intended Use / Indications for Use
The CS100/CS100i and CS300 Intra-Aortic Balloon Pumps are indicated for acute coronary syndrome, cardiac and non-cardiac surgery, or complications of heart failure.
Product codes (comma separated list FDA assigned to the subject device)
DSP
Device Description
The CS100/CS100i and CS300 Intra-Aortic Balloon Pumps (IABPs) are cardiac assist devices. The IABP supports the heart's left ventricle by increasing coronary perfusion and reducing left ventricular work. Coronary perfusion is increased by augmenting blood pressure during the diastolic phase of the cardiac cycle. This increase in aortic pressure promotes more blood flow through the coronary arteries. Left ventricular work is reduced by decreasing aortic end-diastolic pressure and reducing resistance to ventricular ejection, resulting in a decrease in blood pressure during the systolic phase of the cardiac cycle. These beneficial effects are caused by the inflation and deflation of an intra-aortic balloon (IAB) in the patient's descending aorta. The balloon's inflation and deflation must be properly synchronized with the cardiac cycle. IAB inflation is initiated at the onset of diastole at the dicrotic notch and remains inflated through diastole. The IAB is then deflated at, or just prior to, the onset of systole and the balloon remains deflated throughout systole. Hence, the therapy is also referred to as counterpulsation. This is the same intended use as other IABPs.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Prescription Use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The results of the tests conducted demonstrate that the modified CS100/CS100i and CS300 Intra-Aortic Balloon Pumps perform as intended. Datascope Corp. development process required that the following activities be completed during the development of the modified CS100/CS100i and CS300 Intra-Aortic Balloon Pumps: Requirements specification review, Performance testing, Design verification and validation.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.3535 Intra-aortic balloon and control system.
(a)
Identification. An intra-aortic balloon and control system is a prescription device that consists of an inflatable balloon, which is placed in the aorta to improve cardiovascular functioning during certain life-threatening emergencies, and a control system for regulating the inflation and deflation of the balloon. The control system, which monitors and is synchronized with the electrocardiogram, provides a means for setting the inflation and deflation of the balloon with the cardiac cycle.(b)
Classification. (1) Class II (special controls) when the device is indicated for acute coronary syndrome, cardiac and non-cardiac surgery, or complications of heart failure. The special controls for this device are:(i) Appropriate analysis and non-clinical testing must be conducted to validate electromagnetic compatibility and electrical safety of the device;
(ii) Software verification, validation, and hazard analysis must be performed;
(iii) The device must be demonstrated to be biocompatible;
(iv) Sterility and shelf-life testing must demonstrate the sterility of patient-contacting components and the shelf life of these components;
(v) Non-clinical performance evaluation of the device must demonstrate mechanical integrity, durability, and reliability to support its intended purpose; and
(vi) Labeling must include a detailed summary of the device- and procedure-related complications pertinent to use of the device.
(2) Class III (premarket approval) when the device is indicated for septic shock and pulsatile flow generation.
(c)
Date premarket approval application (PMA) or notice of completion of product development protocol (PDP) is required. A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before March 31, 2014, for any intra-aortic balloon and control system indicated for septic shock or pulsatile flow generation that was in commercial distribution before May 28, 1976, or that has, on or before March 31, 2014, been found to be substantially equivalent to any intra-aortic balloon and control system indicated for septic shock or pulsatile flow generation that was in commercial distribution before May 28, 1976. Any other intra-aortic balloon and control system indicated for septic shock or pulsatile flow generation shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters 'FDA' in a blue square, followed by the words 'U.S. FOOD & DRUG ADMINISTRATION' in blue text.
October 12, 2017
Datascope Corp. Helder Sousa Manager, Regulatory Affairs 1300 MacArthur Blvd. Mahwah, New Jersey 07430
Re: K172305
Trade/Device Name: CS100/CS100i Intra-Aortic Balloon Pump, CS300 Intra-Aortic Balloon Pump Regulation Number: 21 CFR 870.3535 Regulation Name: Intra-aortic balloon and control system Regulatory Class: Class II Product Code: DSP Dated: September 22, 2017 Received: September 25, 2017
Dear Helder Sousa:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevicesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely,
Nicole G. Ibrahim -S
for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications For Use
510(k) Number (if known): K172305
Device Name: CS100/CS100i and CS300 Intra-Aortic Balloon Pumps
- The CS100/CS100i and CS300 Intra-Aortic Balloon Pumps are Indications For Use: indicated for acute coronary syndrome, cardiac and non-cardiac surgery, or complications of heart failure.
Prescription Use _____________________________________________________________________________________________________________________________________________________________ (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________ (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
3
CS100/CS100i AND CS300 INTRA-AORTIC BALLOON PUMPS 510(k) Summary
Prepared in accordance with 21 CFR Part 807.92
510(k) Number: K172305
GENERAL INFORMATION
Submitter's name and address: Datascope Corp. 1300 MacArthur Blvd. Mahwah, NJ 07430 Helder A. Sousa Contact person and telephone number: Manager, Regulatory Affairs Phone: (973) 709-7465 Fax: (973) 629-1325 Email: helder.sousa@getinge.com Date prepared: July 28, 2017
DEVICE INFORMATION:
| Trade Name: | CS100/CS100i and CS300 Intra-Aortic Balloon Pump |
|---|---|
| Common/Generic Name: | Intra-Aortic Balloon Pump (IABP) |
| Classification Name: | Intra-Aortic Balloon and control system |
| Regulation Number: | 21 CFR 870.3535 |
| Regulatory Class: | Class II |
| Product Code: | DSP |
PREDICATE DEVICE INFORMATION:
CS100/CS100i and CS300 Intra-Aortic Balloon Pumps (K031636 and K063525)
DEVICE DESCRIPTION:
The CS100/CS100i and CS300 Intra-Aortic Balloon Pumps (IABPs) are cardiac assist devices. The IABP supports the heart's left ventricle by increasing coronary perfusion and reducing left ventricular work. Coronary perfusion is increased by augmenting blood pressure during the diastolic phase of the cardiac cycle. This increase in aortic pressure promotes more blood flow through the coronary arteries. Left ventricular work is reduced by decreasing aortic end-diastolic pressure and reducing resistance to ventricular ejection, resulting in a decrease in blood pressure during the systolic phase of the cardiac cycle.
4
These beneficial effects are caused by the inflation and deflation of an intra-aortic balloon (IAB) in the patient's descending aorta. The balloon's inflation and deflation must be properly synchronized with the cardiac cycle. IAB inflation is initiated at the onset of diastole at the dicrotic notch and remains inflated through diastole. The IAB is then deflated at, or just prior to, the onset of systole and the balloon remains deflated throughout systole. Hence, the therapy is also referred to as counterpulsation. This is the same intended use as other IABPs.
INDICATIONS FOR USE:
The CS100/CS100i and CS300 Intra-Aortic Balloon Pumps are indicated for acute coronary syndrome, cardiac and non-cardiac surgery, or complications of heart failure.
COMPARISON OF TECHNOLOGICAL CHARACTERISTICS TO PREDICATES:
The modified CS100/CS100i and CS300 Intra-Aortic Balloon Pumps are substantially equivalent to the CS100/CS100i and CS300 Intra-Aortic Balloon Pumps (K031636 and K063525).
The changes essentially consist essentially consist of a revised blood detection software function to implement an automatic repeat of the autofill process without the need for operator intervention or system shutdown while continuing to use the optical blood detection sensor to monitor for blood in the catheter.
PERFORMANCE DATA:
The results of the tests conducted demonstrate that the modified CS100/CS100i and CS300 Intra-Aortic Balloon Pumps perform as intended.
Datascope Corp. development process required that the following activities be completed during the development of the modified CS100/CS100i and CS300 Intra-Aortic Balloon Pumps:
- Requirements specification review ●
- . Performance testing
- . Design verification and validation
CLINICAL TESTS:
There was no clinical evaluation of the modified device.
Conclusion:
Based upon the information submitted in this Special 510(k) premarket notification, the modified device is substantially equivalent to the currently marketed CS100/CS100i andCS300 Intra-Aortic Balloon Pumps. The CS100/CS100i and CS300 IABPs with the revised software is similar to the predicate device in the intended use and the fundamental scientific technology of the device. The design verification and validation testing established that the CS100/CS100i and CS300 IABPs with the revised software performs as well as the predicate device.